Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3327

1.

Multiparametric MRI - local staging of prostate cancer and beyond.

Caglic I, Kovac V, Barrett T.

Radiol Oncol. 2019 May 8. pii: /j/raon.ahead-of-print/raon-2019-0021/raon-2019-0021.xml. doi: 10.2478/raon-2019-0021. [Epub ahead of print]

PMID:
31103999
2.

The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17.

PMID:
31099673
3.

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 May 10;114:107-116. doi: 10.1016/j.ejca.2019.04.007. [Epub ahead of print]

PMID:
31082669
4.

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.

Edler von Eyben F, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP.

Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29.

5.

Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody.

Carrasquillo JA, Fine B, Pandit-Taskar N, Larson SM, Fleming S, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gonen M, Williams S, Danila DC, Morris MJ.

J Nucl Med. 2019 May 3. pii: jnumed.118.222844. doi: 10.2967/jnumed.118.222844. [Epub ahead of print]

PMID:
31053681
6.

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ.

Prostate. 2019 May 2. doi: 10.1002/pros.23822. [Epub ahead of print]

PMID:
31045266
7.

Ultrafast bone scintigraphy scan for detecting bone metastasis using a CZT whole-body gamma camera.

Yamane T, Kondo A, Takahashi M, Miyazaki Y, Ehara T, Koga K, Kuji I, Matsunari I.

Eur J Nucl Med Mol Imaging. 2019 May 1. doi: 10.1007/s00259-019-04329-0. [Epub ahead of print]

PMID:
31044266
8.

Dual-time-point 64 Cu-PSMA-617-PET/CT in patients suffering from prostate cancer.

Hoberück S, Wunderlich G, Michler E, Hölscher T, Walther M, Seppelt D, Platzek I, Zöphel K, Kotzerke J.

J Labelled Comp Radiopharm. 2019 May 1. doi: 10.1002/jlcr.3745. [Epub ahead of print]

PMID:
31042811
9.

Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer.

Amoako YA, Hammond ENB, Assasie-Gyimah A, Laryea DO, Ankrah A, Amoah G.

World J Nucl Med. 2019 Apr-Jun;18(2):143-148. doi: 10.4103/wjnm.WJNM_38_18.

10.

Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.

Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA.

AJR Am J Roentgenol. 2019 Apr 30:1-8. doi: 10.2214/AJR.18.20699. [Epub ahead of print]

PMID:
31039025
11.

Clinical impact of lower limb imaging in 68Ga-PSMA PET-CT for patients with prostate cancer.

Has Simsek D, Sanli Y, Kuyumcu S, Engin MN, Buyukkaya F, Demirci E.

J Nucl Med Technol. 2019 Apr 24. pii: jnmt.118.224303. doi: 10.2967/jnmt.118.224303. [Epub ahead of print]

PMID:
31019043
12.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

13.

Erratum to "Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients".

Scimeca M, Urbano N, Bonfiglio R, Mapelli SN, Catapano CV, Carbone GM, Ciuffa S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E.

Contrast Media Mol Imaging. 2019 Mar 11;2019:7843735. doi: 10.1155/2019/7843735. eCollection 2019.

14.

Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.

Haran C, McBean R, Parsons R, Wong D.

J Med Imaging Radiat Oncol. 2019 Apr 11. doi: 10.1111/1754-9485.12885. [Epub ahead of print]

PMID:
30972933
15.

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S.

Eur Urol Oncol. 2019 Feb;2(1):47-76. doi: 10.1016/j.euo.2018.09.010. Epub 2018 Oct 24. Review.

PMID:
30929846
16.

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.

Krimphove MJ, Theissen LH, Cole AP, Preisser F, Mandel PC, Chun FKH.

World J Mens Health. 2019 Mar 5. doi: 10.5534/wjmh.180133. [Epub ahead of print] Review.

17.

MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer.

Wang Y, Yu B, Zhong F, Guo Q, Li K, Hou Y, Lin N.

Magn Reson Imaging. 2019 Mar 24;60:76-84. doi: 10.1016/j.mri.2019.03.007. [Epub ahead of print]

PMID:
30917943
18.

Percutaneous Microwave Ablation and Cementoplasty: Clinical Utility in the Treatment of Painful Extraspinal Osseous Metastatic Disease and Myeloma.

Deib G, Deldar B, Hui F, Barr JS, Khan MA.

AJR Am J Roentgenol. 2019 Mar 27:1-8. doi: 10.2214/AJR.18.20386. [Epub ahead of print]

PMID:
30917019
19.

Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response.

Roque V, Jessop M, Pereira L, Gape P, Dizdarevic S, Sousa E, Carolino E.

Nucl Med Commun. 2019 Jun;40(6):588-596. doi: 10.1097/MNM.0000000000001005.

PMID:
30908340
20.

Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.

Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X, Emberton M, Sanchez-Salas R, Cathcart P.

Eur Urol. 2019 Mar 20. pii: S0302-2838(19)30193-9. doi: 10.1016/j.eururo.2019.03.007. [Epub ahead of print]

PMID:
30904357

Supplemental Content

Loading ...
Support Center